Value-Based Pricing For Treatments And Vaccines In The Context of COVID-19

Referencing ICER’s white paper and webinar series on the same topic, researchers at Tufts’ Center for the Evaluation of Value and Risk in Health (CEVR) reviewed several alternative models for pricing treatments and vaccines during a pandemic situation (e.g., cost-recovery, monetary prizes, advanced market commitments, cost-effectiveness, etc.) and weighed their various advantages, disadvantages, and considerations for optimal implementation. Read more here.

(Source: Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic Peter Neumann, Joshua T. Cohen, David D. Kim, and Daniel A. Ollendorf Health Affairs)